1
Country: Switzerland | Funding: $200M
Windward Bio develops long-acting bispecific antibodies, targeting validated biology in respiratory and dermatological conditions. It's lead candidate, a twice-yearly anti-TSLP agent dubbed WIN378 is undergoing clinical trial to treat asthma and chronic obstructive pulmonary disease. The pipeline also includes WIN027, a clinical-stage, long-acting anti-TSLPxIL-13 bispecific with broad therapeutic potential across immunological diseases
Windward Bio develops long-acting bispecific antibodies, targeting validated biology in respiratory and dermatological conditions. It's lead candidate, a twice-yearly anti-TSLP agent dubbed WIN378 is undergoing clinical trial to treat asthma and chronic obstructive pulmonary disease. The pipeline also includes WIN027, a clinical-stage, long-acting anti-TSLPxIL-13 bispecific with broad therapeutic potential across immunological diseases
2
Country: USA | Funding: $180M
ILiAD is a clinical-stage biotechnology company focused on the prevention and treatment of disease caused by Bordetella Pertussis.
ILiAD is a clinical-stage biotechnology company focused on the prevention and treatment of disease caused by Bordetella Pertussis.
3
Country: USA | Funding: $295.5M
Endeavor is a clinical-stage company developing a best-in-class Hedgehog inhibitor for Idiopathic Pulmonary Fibrosis.
Endeavor is a clinical-stage company developing a best-in-class Hedgehog inhibitor for Idiopathic Pulmonary Fibrosis.
4
Country: USA | Funding: $253M
Diagonal Therapeutics develops agonist antibody-based drugs designed to correct abnormal signaling in severe genetic diseases such as hereditary hemorrhagic telangiectasia. The company is also exploring its antibody as a treatment for the underlying cause of pulmonary arterial hypertension. It has demonstrated significant disease-modifying activity in several preclinical models of NHT and PAH and restore normal signaling in patient-derived cells. The company claims its antibodies are highly specific, easy to manufacture and convenient for use in patients, with potential for modification during disease management.
Diagonal Therapeutics develops agonist antibody-based drugs designed to correct abnormal signaling in severe genetic diseases such as hereditary hemorrhagic telangiectasia. The company is also exploring its antibody as a treatment for the underlying cause of pulmonary arterial hypertension. It has demonstrated significant disease-modifying activity in several preclinical models of NHT and PAH and restore normal signaling in patient-derived cells. The company claims its antibodies are highly specific, easy to manufacture and convenient for use in patients, with potential for modification during disease management.
5
Country: UK | Funding: $205.5M
Pulmocide develops inhaled medications for the treatment of viral and fungal respiratory tract infections. The company's lead drug, opelconazole, is in Phase 3 clinical trials for the treatment of patients with invasive pulmonary aspergillosis. Aspergillus is a genus of fungi whose spores are airborne and can cause severe, often life-threatening, lung disease in people with weakened immune systems or pre-existing lung conditions. Opelconazole has received several FDA approvals that may expedite its development and/or review, including orphan drug designation, fast-track designation, and qualified infectious disease product (QIDP) designation. It has also received orphan drug designation in the European Union.
Pulmocide develops inhaled medications for the treatment of viral and fungal respiratory tract infections. The company's lead drug, opelconazole, is in Phase 3 clinical trials for the treatment of patients with invasive pulmonary aspergillosis. Aspergillus is a genus of fungi whose spores are airborne and can cause severe, often life-threatening, lung disease in people with weakened immune systems or pre-existing lung conditions. Opelconazole has received several FDA approvals that may expedite its development and/or review, including orphan drug designation, fast-track designation, and qualified infectious disease product (QIDP) designation. It has also received orphan drug designation in the European Union.
6
Country: UK | Funding: £18M
A drug discovery and development company focused on advancing novel approaches for severe respiratory conditions
A drug discovery and development company focused on advancing novel approaches for severe respiratory conditions
7
Country: UK | Funding: £68.8M
Enterprise Therapeutics is a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases. In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlying mechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life.
Enterprise Therapeutics is a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases. In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlying mechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life.
8
Country: USA | Funding: $53.9M
Lung Therapeutics pursues innovative treatments for underserved, life-threatening lung conditions. Our therapies for Idiopathic Pulmonary Fibrosis and Loculated Pleural Effusion bring hope to patients whose only treatment options may be invasive surgery or costly and ineffective drugs. We aim to create better pharmaceutical treatment options for IPF, LPE, and other underserved lung conditions.
Lung Therapeutics pursues innovative treatments for underserved, life-threatening lung conditions. Our therapies for Idiopathic Pulmonary Fibrosis and Loculated Pleural Effusion bring hope to patients whose only treatment options may be invasive surgery or costly and ineffective drugs. We aim to create better pharmaceutical treatment options for IPF, LPE, and other underserved lung conditions.
9
Country: Singapore | Funding: $24.8M
ABM Respiratory Care is a medical device startup that develops ventilation solutions for people suffering from pulmonary diseases.
ABM Respiratory Care is a medical device startup that develops ventilation solutions for people suffering from pulmonary diseases.
10
Country: USA | Funding: $23.3M
Pneuma Respiratory is focused on creating therapeutic treatments for diseases of the lungs using a digital first platform for inhaled drug delivery. Our focus is to improve the potential effectiveness of currently available and novel drugs, with the initial targets being approved therapeutics for asthma and COPD.
Pneuma Respiratory is focused on creating therapeutic treatments for diseases of the lungs using a digital first platform for inhaled drug delivery. Our focus is to improve the potential effectiveness of currently available and novel drugs, with the initial targets being approved therapeutics for asthma and COPD.
11
Country: USA | Funding: $22M
Telesair creates Respiratory Humidifier, designed for use in the ICU, and support the development of a new product that aims to help patients leave the hospital more quickly and stay at home safely.
Telesair creates Respiratory Humidifier, designed for use in the ICU, and support the development of a new product that aims to help patients leave the hospital more quickly and stay at home safely.
12
Country: USA | Funding: $16.8M
Cohero developed a connected spirometer to assess lung function and medication adherence in asthma and COPD patients. It was designed to be a clinical grade medical device to function as a barometer for lung function. It also produced a patient-facing app that helps users track their data.
Cohero developed a connected spirometer to assess lung function and medication adherence in asthma and COPD patients. It was designed to be a clinical grade medical device to function as a barometer for lung function. It also produced a patient-facing app that helps users track their data.
13
Country: USA | Funding: $15.7M
Sentrian developed a biosensor supported by cloud technology and machine to detect deteriorating health of patients earlier.
Sentrian developed a biosensor supported by cloud technology and machine to detect deteriorating health of patients earlier.
14
Country: New Zealand | Funding: $15.4M
Adherium provides digital health solutions for respiratory conditions including asthma and COPD.
Adherium provides digital health solutions for respiratory conditions including asthma and COPD.
15
Country: Cyprus | Funding: €10M
Liita Care is a MedTech company focused on Respiratory Health. We are committed to improve quality of life for patients and healthy consumers by developing and manufacturing new and better therapies and medical devices for respiratory health management.
Liita Care is a MedTech company focused on Respiratory Health. We are committed to improve quality of life for patients and healthy consumers by developing and manufacturing new and better therapies and medical devices for respiratory health management.
16
Country: Portugal | Funding: €4.8M
C-mo is the solution providing a complete assessment of cough, adressing key use-cases across the patient management lifecycle.
C-mo is the solution providing a complete assessment of cough, adressing key use-cases across the patient management lifecycle.
17
Country: Germany | Funding: €4.7M
VisionHealth supports patients with chronic lung diseases who are dependent on their inhaler.
VisionHealth supports patients with chronic lung diseases who are dependent on their inhaler.
18
Country: USA | Funding: $5M
LifeMap Solutions develops a m-Health platform that integrates disparate sources of information to generate an accurate picture of an individual's health. One of the primary apps is COPD Navigator app.
LifeMap Solutions develops a m-Health platform that integrates disparate sources of information to generate an accurate picture of an individual's health. One of the primary apps is COPD Navigator app.
19
Country: Canada
Breathe-Global Devices intends to build inexpensive, easy-to-use, negative-pressure assisted breathing devices that can be worn without limiting the user’s everyday activities.
Breathe-Global Devices intends to build inexpensive, easy-to-use, negative-pressure assisted breathing devices that can be worn without limiting the user’s everyday activities.
